Tenormin 50 mg
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest that Tenormin (atenolol) 50 mg is bioequivalent to other atenolol formulations, effectively reduces blood pressure and ocular tension, and has lower variability in pharmacokinetics compared to metoprolol.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta19 papers analyzed
Tenormin 50 mg: Clinical Insights and Bioequivalence
Atenolol (Tenormin) 50 mg: Overview and Clinical Effects
Atenolol, marketed under the brand name Tenormin, is a beta-adrenoceptor blocker commonly prescribed for managing hypertension and other cardiovascular conditions. A study comparing atenolol (50 mg and 100 mg) with methyldopa in healthy volunteers found that atenolol significantly reduced systolic and diastolic blood pressure and pulse rate without affecting reaction time, critical flicker frequency, or causing drowsiness, unlike methyldopa. This suggests that atenolol is effective in lowering blood pressure without central nervous system side effects.
Bioequivalence of Atenolol 50 mg Formulations
Comparative Bioavailability Studies
Several studies have evaluated the bioequivalence of different atenolol 50 mg formulations. A study involving Korean volunteers compared a generic product, Ditent®, with Tenormin® and found no significant differences in pharmacokinetic parameters such as peak plasma concentration (Cmax), time to reach peak plasma concentration (Tmax), and area under the plasma concentration-time curve (AUC). Both products were within the bioequivalence limits, indicating similar rates and extents of absorption. Another study comparing Sinil Atenolol Tablets with Tenormin® also concluded bioequivalence, with comparable pharmacokinetic profiles.
Bioequivalence in Different Populations
A study conducted on Thai volunteers compared Prenolol with Tenormin® and found that both 50 mg and 100 mg preparations were bioequivalent, with similar AUC and Cmax values. These findings reinforce the consistency of atenolol's pharmacokinetic properties across different populations and generic formulations.
Ocular Hypotensive Effects
Atenolol has also been studied for its ocular hypotensive effects. A controlled double-blind study demonstrated that a single 50 mg dose of atenolol significantly reduced ocular tension for about 7 hours in patients with glaucoma, with the maximum effect observed 5 hours post-ingestion. This suggests potential benefits of atenolol in managing ocular hypertension.
Pharmacokinetics and Variability
A study comparing the pharmacokinetics of atenolol and metoprolol found that atenolol exhibited lower variability in plasma concentrations, which may translate to more predictable therapeutic effects. Additionally, the pharmacokinetics of (S)-atenolol and (R,S)-atenolol (Tenormin) were studied, showing that both formulations effectively attenuate exercise-induced increases in heart rate and systolic blood pressure.
Combination Therapies
In elderly hypertensive patients, a combination of atenolol (50 mg) with a potassium-sparing diuretic (hydrochlorothiazide and amiloride hydrochloride) was effective in reducing blood pressure. Another study found that combining atenolol with chlorthalidone (Tenoretic Mite) resulted in better blood pressure control compared to atenolol alone, particularly in older patients and females.
Conclusion
Atenolol (Tenormin) 50 mg is a well-tolerated and effective beta-blocker for managing hypertension and other cardiovascular conditions. It demonstrates consistent bioequivalence across various generic formulations and populations, with additional benefits in ocular hypertension and combination therapies. Its predictable pharmacokinetic profile further supports its clinical utility.
Sources and full results
Most relevant research papers on this topic
